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A serum ELISA using a monoclonal antibody that detects a MUC5AC-related antigen (NPC-1C antigen) expressed by pancreatic
andcolorectal cancerwas developed. The NPC-1C antibody reacts with speciﬁc epitopes expressed by tumor-associatedMUC5AC
thatdoes notappear onMUC5AC fromnormaltissues.Basedonobservationsofa highlyspeciﬁc antibody, wetested the ELISAto
diﬀerentiateserumfromhealthyblooddonorscomparedto serumfrompatientswithcolorectalorpancreaticcancer.Additionally,
patient tumor tissue was stained to examine the expression pattern of MUC5AC-related antigen in pancreatic and colorectal
cancers. The results indicate the NPC-1C antibody ELISA distinguished serum of cancer patients from normal donors with
very good sensitivity and speciﬁcity. Most patient’s tumor biopsy exhibited NPC-1C antibody reactivity, indicating that tumor-
associated MUC5AC antigen from tumor is shed into blood, where it can be detected by the NPC-1C antibody ELISA. This serum
test provides a new tool to aid in the diagnosis of these cancers and immune monitoring of cancer treatment regimens.
1.Introduction
The early diagnosis of colorectal and pancreatic cancers
remains an area of high unmet medical need, as underscored
by theUS estimated combined,annual death rate of>89,000
[1]. Although the serum marker CA19-9 is elevated in the
majority of pancreatic cancer patients, the speciﬁcity of
CA19-9 is limited. CA19-9 is frequently elevated in patients
with various benign pancreaticobiliary disorders [2–4]. As a
result of all of these issues, CA19-9 is not recommended as a
screening test for pancreatic cancer [5]. The American Col-
lege of Gastroenterology (ACG) recommends colonoscopy
as the preferred screening/prevention test for colorectal
cancer. Noninvasive fecal immunochemical tests are only
recommended for patients who decline cancer prevention
tests [6]. Currently, there is no consensus for screening for
the early detection of pancreatic cancer. Unlike colorectal
cancer, the majority cases of pancreatic cancer are detected
when a patient is symptomatic which often times represents
late stage cancer, resulting in an overall 5 year survival of
less than 5% [1]. The majority of colorectal and pancreatic
cancer patients are diagnosed utilizing invasive procedures
that are expensive, and usually reveal the diagnosis later in
the disease process. Newer approaches are being investigated
that could allow for earlier detection of disease, in a cost-
eﬀective manner, that furthermore could result in better
outcomes for patients with these diseases.
As an alternative diagnostic approach, we developed an
ELISA using a promising novel tumor-speciﬁc monoclonal
antibody generated against a clinically tested human colon
cancer vaccine. NPC-1 is a monoclonal antibody that was
derived from a Tumor Associated Antigen- (TAA-) based
vaccine that was previously tested in Phase I-II clinical
trials performed in the United States [7–9]. The TAA
utilized in these studies was derived from pooled allogeneic
colon cancer specimens from multiple patients, which was
obtainedpostoperatively.Cellmembraneswereisolatedfrom
the tumor, and proteins from solubilized membranes were
prepared by sonication and Sephadex G-200 chromatogra-
phy. Semipuriﬁed TAAs were identiﬁed by in vitro and in
vivo testing in colon cancer patients and healthy volunteers
for cell-mediated immunoreactivities. The colon TAA was2 Journal of Biomedicine and Biotechnology
detected in fetal intestine and cell membranes, and was
localized on tumor cell membranes. Using discontinuous,
gradient gel electrophoresis, both colon TAA and CEA were
separated and cross-compared. The TAA was shown to be
distinct from CEA [8]. The cDNA encoding the NPC-1
antibody was cloned from hybridoma cells, chimerized by
genetic engineering, and expressed in a heterologous expres-
sion system (Chinese hamster ovary cells). The puriﬁed
recombinant chimeric antibody is denoted NPC-1C.
The NPC-1C antibody binds to a protein antigen
biomarker expressed by human colorectal and pancreatic
tumors. In immunohistochemical testing, NPC-1C did not
react signiﬁcantly with tissues from healthy donors or other
types of cancer. Furthermore, as discussed below, the NPC-
1C antibody ELISA developed can distinguish serum of
patients with colorectal or pancreatic cancer from healthy
volunteers, thereby providing the rationale for accelerated
development and testing of the variant MUC5AC (NPC-
1C antigen) detection assay. The test may have application
in diagnosis and treatment monitoring of patients with
pancreatic or colorectal cancers.
2.Materialsand Methods
2.1. ELISA Test. A sandwich ELISA was developed using
NPC-1C antibody as the capture reagent. Biotin-labeled
NPC-1C was used as the detection antibody. This homol-
ogous antibody format was possible due to the discovery
of multiple NPC-1C antigen-binding sites expressed by
the cancer-associated MUC5AC-related (NPC-1C) antigen.
Serum samples were procured from various commercial and
private sources under appropriate IRB-reviewed protocols.
The assay developed here used serum from colorectal and
pancreatic cancer patients, and serum from healthy blood
donors.
Microtiter plates (96-well Nunc Maxisorp) were coated
with puriﬁed unlabeled NPC-1C antibody at 10µg/mL in
0.5M sodium carbonate pH 9.5 overnight at 25◦C. Plates
were then blocked with 1% skim milk made in Tris-Buﬀered
Saline (TBS) containing 5mM EDTA and 1% sucrose for
4h o u r sa t2 5 ◦C. Plates prepared in this manner could
be stored dried and sealed for at least 12 months. All
dilutions were made in ImmunoBooster buﬀers (Bioworld
Consulting Laboratories, LLC) supplemented with 20mM
EDTA. Wash buﬀer was TBS containing 0.05% Tween-20
nonionic detergent. A detergent extract of cultured human
LS174T colorectal tumor cells was used as a source of
NPC-1C antigen to derive a standard curve. Units were in
cells/well. Extracts derived from human pancreatic CFPAC-1
tumor cells or human lung A549 tumor cells were generated
similarly. All tumor cell lines were purchased from American
Type CultureCollection (Manassas, VA) and grown in RPMI
medium containing 10% FBS (heat-inactivated) with 8mM
glutamine. To measure directb i n d i n go fN P C - 1 Ca n t i b o d y
to the variant MUC5AC (NPC-1C) antigen, CFPAC-1 cells
w e r eg r o w ni ns e r u m - f r e em e d i u mf o r5d a y sa n dt h e
conditioned medium was ﬁltered and stored in one large lot
at 4◦C.
The sandwich ELISAs were performed by diluting the
cell extract standard on each plate, next to patient or
normal serum samples diluted 1:24 in the diluent. All
incubations were performed at 25◦C and all volumes were
100uL per well. The plates were incubated for 15 minutes
and washed three times with wash buﬀer. The biotin-labeled
NPC-1C antibody was then added to the wells at 1µg/mL,
incubated for 15 minutes, and plates were washed three
times.Peroxidase-conjugatedstreptavidin(1:5,000dilution)
was added to the plates for 15 minutes, and plates were
washed three times with wash buﬀer and two times with
TBS. The assay was developed by the addition of TMB
substrate (BioFX Laboratories Inc.) to the plates, incubation
for 15 minutes, then the color reaction was stopped with
the addition of 0.5M sulfuric acid. The data was acquired
by measuring absorbance at 450nm. The data was ana-
lyzed using GraphPad Prism or Microsoft Excel software
programs.
NPC-1C antibody-binding competition assays were per-
formed by coating microtiter plates with serum-free con-
ditioned medium from CFPAC-1 tumor cells shown to
secrete the variant MUC5AC antigen into the culture
medium. Following a blocking step as described above,
a solution of 1µg/mL NPC-1C antibody was mixed with
serial dilutions of conditioned medium from CFPAC-1,
LS174T, and A549 tumor cells. The ELISA was devel-
oped using anti-human IgG peroxidase-conjugated anti-
body followed by TMB substrate incubation as described
above. Inhibition curves were plotted using Microsoft
Excel.
2.2. Immunohistochemistry. Tumor biopsy specimens from
colorectal, pancreatic, or lung cancer patients were deparaf-
ﬁnized at 60◦C for 30 minutes prior to staining with NPC-
1Cantibody. Subsequently,all staining stepswere carried out
at 25◦C. Slides (4 microns thick) were blocked with Peroxo-
Bloc inhibitor (Zymed Laboratories) for 2 minutes, rinsed
with phosphate-buﬀered saline (PBS), and blocked with
CAS (Zymed Laboratories) for an additional 10 minutes.
Slides were stained with 10µg/mL of biotin-labeled NPC-
1C antibody for 1 hour, and washed three times with PBS
containing 0.05% Tween-20 nonionic detergent. Previous
titration of biotinylated-NPC-1C antibody demonstrated
10µg/mL to be an optimal concentration for immunohis-
tochemical detection of the variant MUC5AC antigen. A
1:400 dilution of peroxidase-conjugated streptavidin (Dako
North America, Inc.) was then applied to the slides for
30 minutes and slides were washed 3 times. A solution
of DAB (Zymed Laboratories) was applied for 3 minutes
then rinsed with PBS. A solution of hematoxylin was
then applied for 3 minutes and rinsed with tap water
until clear. The slides were dehydrated with xylene and a
coverslip was added using Permount mounting medium.
Additional consecutive slides were stained with human
cytokeratin AE1/AE3 (Abcam plc) as a positive control, and
human IgG1 isotype as a negative control (AXXORA, llc).
The anti-MUC5AC antibody (clone 45M1) used to stain
lung tumor tissue (10µg/mL) was purchased from Abcam
plc.Journal of Biomedicine and Biotechnology 3
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Figure 1: NPC-1C antibody reacts with a colorectal and pancreatic
cancer-speciﬁc antigen. NPC-1C antigen secreted by serum-starved
CFPAC-1cells wasused to coata96-well microtiterplate. Following
ablockingstep ,1µg/mLofNPC-1Cantibodywasaddedtothewells
in the absence or presence of increasing amounts of conditioned
medium from CFPAC-1 (pancreatic), LS174T (colorectal), or A549
(lung) cells to compete for NPC-1C binding to the coated antigen.
The ELISA was developed by adding anti-human IgG-conjugated
peroxidase reagent followed by TMB substrate.
3.Results
The NPC-1 antibody was generated in mice immunized with
a preparation of pooled human colon tumor tissue extract.
Hundreds of hybridomas were screened for cancer-speciﬁc
characteristics such as binding to tumor tissues and cell
lines, with no cross-reactivity to normal human tissues. The
original murine IgG, NPC-1, was cloned and chimerized by
genetically engineering the mouse variable regions of heavy
and light chains with human IgG1 constant regions of the
heavy and light chains. The resulting chimeric antibody,
NPC-1C, was then expressed in a recombinant Chinese
hamster ovary cell clone for further preclinical and clinical
development.
The NPC-1C antibody was used as an aﬃnity chro-
matography tool to isolate and identify the target antigen
expressed by colorectal and pancreatic tumor cells. It was
shown early that although the murine NPC-1 antibody
was generated against a preparation of colorectal tumor-
associated antigens, the NPC-1 antibody cross-reacted with
pancreatic cancer tissues and cell lines. The target antigen
recognized by NPC-1C was determined to be related to
the mucin 5ac (MUC5AC) protein, a member of the
secreted mucin family of glycoproteins (reviewed in [10]).
We rapidly determined that the variant MUC5AC antigen
was shed into the supernatant of many cultured human
colorectal and pancreatic tumor cells, but not by other
tumor cell lines such as prostate or lung tumor cells. We
therefore examined whether the NPC-1C antibody could
be useful to detect the target MUC5AC-related antigen
in humans aﬄicted with colorectal or pancreatic can-
cer.
To demonstrate by example that the secreted variant
MUC5AC antigen recognized by NPC-1C antibody was
expressed speciﬁcally by colorectal and pancreatic tumor
cells, supernates from LS174T, and CFPAC-1 were admixed
with NPC-1C in a competitive ELISA format. Figure 1
shows that the soluble variant MUC5AC antigen secreted
by LS174T and CFPAC-1 tumor cells could compete eﬀec-
tively with binding to NPC-1C antibody when the variant
MUC5AC antigen was coated on microtiter plates. In
contrast, supernates from human lung A549 tumor cells that
a r ek n o w nt os e c r e t en o r m a lM U C 5 A Cd i dn o tc o m p e t ef o r
binding to NPC-1C antibody. Similar competition curves
were shown with other colorectal and pancreatic tumor cell
lines, but not with another squamous tumor cell line (data
not shown). Together the results demonstrate that NPC-1C
binds speciﬁcally to a variant MUC5AC antigen expressed
by colorectal and pancreatic tumor cells, but not MUC5AC
secreted by other tumor cell types.
Chemical and enzymatic digestion of the NPC-1C
antibody puriﬁed variant MUC5AC antigen revealed that
each molecule of the NPC-1C target contained multiple
epitopes for NPC-1C binding (data not shown). Therefore,
we reasoned that it would be possible to use NPC-1C
as a speciﬁc reagent for both the capture and detection
antibody in a homologous format ELISA. Biotin-labeled
NPC-1C antibody was prepared as the detection reagent and
tested with variant MUC5AC antigen expressed by LS174T
cells. Figure 2 shows that NPC-1C antibody was capable of
measuring the cognate antigen expressed by LS174T in this
ELISAformat.Incontrast,MUC5ACexpressed bylungA549
tumor cells was not detected in the ELISA. Thus, a surrogate
standard MUC5AC-related antigen reagent was generated,
frozen, and used forall subsequentELISAtests. The NPC-1C
antibody immunoreactive antigenisreported here inunitsof
LS174T cells/well equivalent.
The proof-of-concept to demonstrate that the NPC-
1C antibody ELISA test could be utilized to detect the
variant MUC5AC antigen in human serum specimens was
demonstrated with a small number of serum samples
from colorectal cancer patients. Figure 3 shows the results
from ﬁve serum specimens collected from colorectal cancer
patientscompared topooled ABserum from healthy donors.
The results demonstrate a range of variant MUC5ACantigen
shed into the blood of these colorectal cancer patients. In
contrast, pooledABserumfromhealthy donorsdidnot yield
a signiﬁcant signal and was similar to the background levels
for the ELISA. Following this, and other preliminary tests,
an optimum serum dilution of 1:24 was routinely used in
subsequent testing.
A larger number of serum samples were procured to test
the utility of the serum-based ELISA in detecting the variant
MUC5AC antigen. A sampling of 41 colorectal or pancreatic
cancer patient sera was compared with sera collected from
28 normal healthy blood donors. In this population of
cancer patients, blood was collected serially during an
approximately 3-month period for several of the patients
while theywere undergoingvarious treatment regimens with
a medical oncologist. For multiple reasons, blood was not
collected from all patients at all three timepoints. Thus,4 Journal of Biomedicine and Biotechnology
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Figure 2: Development of a surrogate MUC5AC-related antigen
standard. Protein extracted from human LS174T colorectal tumor
cells was prepared to generate a standard curve in the NPC-1C
antigen-capture ELISA. Unlabeled NPC-1C was used to coat a 96-
well microtiter plate. Following a blocking step, a detergent extract
made from human LS174T colorectal tumor cells or human A549
lung tumor cells were incubated on the plates. Biotin-labeled NPC-
1C was then applied to the plates to detect the bound antigen,
followed by development with streptavidin-peroxidase and TMB
incubation steps.
MUC5AC ELISA: patient serum
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Figure 3: NPC-1C antigen detection in colorectal cancer patient
serum. The NPC-1C antigen sandwich ELISA was used to test
control serum pooled from normal donors (AB serum, shown
in open circles with a thick connecting line), in comparison
w i t hs e r u mf r o mﬁ v ei n d i v i d u a l sd i a g n o s e dw i t hc o l o r e c t a lc a n c e r
(shown in various symbols and colors). Serum specimens were
tested at the dilutions indicated on the x-axis.
there were 41 patients that donated blood at their ﬁrst
evaluationby the medical oncologist,followed by 33 patients
that donated their blood at the second visit, and 25 patients
who completed all three blood donations at the third visit.
The majority of specimens tested in this preliminary study
were from patients diagnosed with Stage III or IV disease.
Figure 4 shows the results of testing this larger panel of
colorectal and pancreatic cancer patient serum specimens,
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Figure 4: NPC-1C antigen detection in patients undergoing treat-
ment. Serial blood draws of cancer patients over an approximate
3-month period were tested. The NPC-1C sandwich ELISA was
performed at a 1:24 serum dilution as described in Section 2.
Results are presented as a scatter plot of each experimental
group, with the mean and standard error of the mean. There
were 28 normal sera, 41 colorectal/pancreatic cancer sera at 1-
month, 33 colorectal/pancreatic cancer sera at 2-month, and 25
colorectal/pancreatic cancer sera at 3-month.
compared to a group of normal healthy blood donors.
Analysis of the results demonstrated approximately a 0.7
log diﬀerence between the cancer patients and the healthy
donors at each of the three blood draws. The mean and
standard error of the mean for each control group for
t h ea s s a y sa r eN o r m a l s( 3 5 5± 6 0 ) ,C o l / P a nC a :1 - m o n t h
(1,757 ± 580), Col/Pan Ca: 2-month (1,894 ± 671), Col/Pan
Ca: 3-month (1,293 ± 390). Using the unpaired t-test
(2-tailed) method to evaluate the diﬀerence between the
Normal sera group and the cancer sera groups, the diﬀer-
ences for each comparison were Normal versus 1-month:
P = .0511; Normal versus 2-month: P = .0397; Normal
versus 3-month: P = .0153. Furthermore, using a cut-
oﬀ value of 355cells/well derived from the Normal sera
average, 73% of Col/Pan Ca, 1-month sera were above
the cutoﬀ (30 of 41 samples), and 88% were above the
cutoﬀ in each of the 2-month (29 of 33 samples), and 3-
month (22 of 25 samples) in those groups. Overall, the
samples represent an average of 82% positive above the
cutoﬀ established for the assay. These results show that
the NPC-1C antibody ELISA can distinguish diﬀerences
between serum from normal donors and colorectal or
pancreatic cancer patients, with a promising level of conﬁ-
dence.
The cancer patient population tested in this study was
further stratiﬁed by disease type. Figure 5 shows that there
was no diﬀerence distinguished by the mean NPC-1C anti-
body ELISA results among those patients diagnosed with
colorectal cancer (n = 36) from those patients diagnosed
with pancreatic cancer (n = 5). Both groups separatelyJournal of Biomedicine and Biotechnology 5
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Figure 5: Colorectal and pancreatic cancer sera are detected
similarly by NPC-1C. Serum specimens were sorted according to
patients diagnosed with either colorectal (n = 36) or pancreatic
cancer (n = 5). These were compared to the average of all cancer
specimens and the normal serum specimens.
demonstrated approximately 0.7 log units higher variant
MUC5AC antigen expression levels compared to the group
of healthy donors.
From patients that donated multiple serum samples, the
amount of variant MUC5ACbiomarkerdetected in the assay
was plotted versus the time of the blood draw. As shown in
Figure 6, some patients appeared to express similar amounts
of the variant MUC5AC antigen during the 2- or 3-month
period when blood was drawn (subjects 5, 14, 15, 19, 25,
28, 29), whereas some patients appeared to experience an
increase in this tumor-speciﬁc antigen expression (subjects
1, 2, 7, 33, 39) or a decrease in the biomarker expression
(subjects 18, 22, 23, 28, 34, 36, 40). The signiﬁcance of these
shifts over time are presently unclear, but may be related
to the tumor burden of the patient at the time the blood
was drawn, which may be directly related to the speciﬁc
treatment regimen of individual patients. Thus, the NPC-
1C antibody ELISA may be a useful tool as a treatment
monitoring biomarker assay. It was not possible within the
3-month time period of the blood collections to determine
whether a correlation exists between the rate of variant
MUC5AC increase or decrease and the outcome of the
disease in these patients. This will be the subject of a future
study.
4.Immunohistochemical Analysis
A number of tumor tissue specimens were procured to
examine the level and incidence of variant MUC5ACantigen
expression in colorectal and pancreatic cancer patients.
Biotin-labeled NPC-1C antibody was used at 10µg/mL,
detectedwithstreptavidin-horseradish peroxidaseconjugate,
andmountedonglassslides.Apositivestaining scaleranging
from +1 to +5 was applied to the staining results, evaluated
by light microscopy. Representative examples of the staining
results to detect the variant MUC5AC antigen are shown in
Figure 7. Tissues from normal pancreas and colon showed
no cross-reactive staining with NPC-1C antibody (panels
(a) and (c) resp.). In contrast, tissues from pancreatic and
colorectal tumor biopsies demonstrated speciﬁc staining
of both cytoplasmic and membrane associated antigen
(panels (b) and (d) resp.). In the colorectal cancer tissues,
frequent staining of secreted variant MUC5AC antigen was
observed in the luminal spaces of the tissues (panel (d)).
The tissue speciﬁcity of NPC-1C binding was demonstrated
by the lack of positive staining of lung adenocarcinoma
tissue (panel (f)), whereas a commercially available anti-
MUC5AC antibody shows that the lung tumor tissue
expresses MUC5AC (panel (e)). Thus, while MUC5AC is
k n o w nt ob ee x p r e s s e db yl u n gc e l l s ,t h eN P C - 1 Ca n t i b o d y
does not react with the MUC5AC expressed by lung tumor
tissue.
Tissues stained with NPC-1C antibody were considered
positive (+1 to +5) for 79% of the tumor samples procured
and stained (30 of 38). These staining results are similar to
results from several other studies completed with NPC-1C
antibody using tissue array slides, and both frozen and
paraﬃn-embedded surgical specimens.
5.Discussion
The proof of concept has been established for the value
of the NPC-1C antibody in the detection of the tumor-
associated MUC5AC antigen recognized by NPC-1C anti-
body. This development suggests a new eﬀective, scalable
serum biomarker ELISA for the potential diagnosis and
immunoregulatory monitoring of patients with colorectal
and pancreatic cancer. These results also support further
development and large-scale early Noninvasive diagnostic
screening of healthy populations for colorectal and pancre-
atic cancer.
The preliminary results described here demonstrate
that the NPC-1C antibody can distinguish normal/healthy
serum from serum derived from patients with colorectal or
pancreatic cancer. A better deﬁned cohort of healthy serum
donors may permit improved comparisons regarding assay
speciﬁcity and sensitivity. Interestingly, should the assays be
predictive in diagnosing colorectal and/or pancreatic cancer,
some of the “normal” donors tested in the assays described
here may be predisposed to developing cancer, and the
potential utility of these ELISAs may be underestimated, if
they could detect cancer in asymptomatic persons. Indeed,
while the patient population studied in this report was
predominantly from Stage III and IV cancer patients, we
are currently procuring serum specimens from earlier stage
colorectal and pancreatic cancer patients (Stage I and II)
as well as serum from asymptomatic persons at risk for
developing these types of cancer.
Severalresearch laboratorieshavedemonstratedtheasso-
ciation of aberrantly expressed MUC5AC in colorectal and
pancreatic cancers [11, 12]. Many monoclonal antibodies
that target MUC5AChave beengenerated[13–17]. However,
none of these appear as speciﬁc as the NPC-1C antibody
in deﬁning the variant MUC5AC antigen expressed in
colorectal and pancreatic patient serum as compared with6 Journal of Biomedicine and Biotechnology
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Figure 6: NPC-1C antigen detection in serum during treatment over 3 months. Serum was tested in the NPC-1C sandwich ELISA monthly
from colorectal and pancreatic cancer patients over approximately 3 months during which they were being treated for their disease. Trends
of increases, decreases, and stable biomarker levels were evaluated in each patient.
normal healthy donors, or as compared with MUC5AC
antigen expressed by other tumor types. The reason for this
diﬀerencemay be due,in part, to the speciﬁc epitopethat the
NPC-1C antibody recognizes, which is currently an area of
active investigation.
The assay speciﬁcity using the normal serum samples
presented in this interim report are 71% (8/28 normal
samples above the mean cutoﬀ). The sensitivity for the
NPC-1C antibody ELISA was 82% (18/99 cancer samples
below the mean normal cutoﬀ). Future testing and data
analysiswithnewserumfromhealthydonorsshouldincrease
the speciﬁcities of both serum assays. Importantly, testing
earlier stage cancer patient (Stage I-II) will shed light on the
application of this ELISA to detect cancers earlier, which will
allow earlier interventionsand improve treatment outcomes.
Reviewing the IHC results for each antibody, the tumor
biopsy specimens were collected from patients diagnosed
pathologicallywith StageIIIandIVcolorectalandpancreatic
cancer. The NPC-1C antibody had a sensitivity of 79%
(30 of 38 positive). The chimeric NPC-1C therapeutic
antibody (Ensituximab) is currently being tested in a Phase
I dose escalation clinical trial. As part of the eligibility
criteria for the study, patients with advanced pancreatic
or colorectal cancers must have their tumor biopsy stain
positive for the NPC-1C antigen to be considered eligible
for treatment. The preliminary immunohistochemical data
presented here suggests that approximately 80% of patients
may be treated with the therapeuticbiological NPC-1C. This
truly represents the new frontier of theranostics, where a
biomarker can act as a companion to a speciﬁc therapeutic
product.
The serum ELISA described here may have utility in
monitoring colorectal or pancreatic cancer patients during
the course of a treatment regimen. Patients with pancreatic
cancer are typically treated with gemcitabine, whereas the
treatment options for colorectal cancer patients can include
chemotherapies (5-ﬂuorouracil, FOLFOX, or FOLFIRI) or
biologics such as cetuximab and bevacizumab. The NPC-
1C antibody ELISA may be useful to aid in monitor-
ing the patient responses to such therapies. The results
shown in Figure 6 demonstrate trends for certain patients
that may reﬂect cancer regression, progression, or stable
disease. Once these data are coupled with the disease
status in patients, the correlation may become apparent.
Serum-based detection of colorectal and pancreatic cancer
biomarkers will improve the chances for early detectionJournal of Biomedicine and Biotechnology 7
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Figure 7: Immunohistochemical staining using NPC-1C. NPC-1C staining of normal human pancreatic (a), normal human colorectal (c),
pancreatic cancer (b), and colorectal cancer (d). The brown stained areas indicate immunoreactivity of NPC-1C with the cancer-speciﬁc
MUC5AC antigen. Lung adenocarcinoma stained with a commercially available anti-human MUC5AC antibody (e) or with NPC-1C (f),
demonstrating that the NPC-1C antibody does not recognize the lung adenocarcinoma-associatedMUC5AC.
of these deadly diseases. Current diagnostic methods are
invasive, expensive, and often inconclusive. The preliminary
results with the NPC-1C ELISA to speciﬁcally detect tumor-
associated MUC5AC may improve the diagnosis of these
solid tumors as well as aid in the immune monitoring
and prognosis of patients undergoing treatment of their
disease.
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